The global market for ventricular hypertrophy treatment is projected to rise considerably in the coming years. This development can be attributed to a blend of factors, including an increasing elderly demographic, escalating incidence of cardiovascular diseases, and advancements in medical interventions. The is fueled by a desire for effective cur